JP2018508475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508475A5 JP2018508475A5 JP2017536240A JP2017536240A JP2018508475A5 JP 2018508475 A5 JP2018508475 A5 JP 2018508475A5 JP 2017536240 A JP2017536240 A JP 2017536240A JP 2017536240 A JP2017536240 A JP 2017536240A JP 2018508475 A5 JP2018508475 A5 JP 2018508475A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- binding
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 239000012634 fragment Substances 0.000 claims description 86
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 33
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 33
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- -1 ICOS Proteins 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000003915 cell function Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 claims description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102000024905 CD99 Human genes 0.000 claims description 2
- 108060001253 CD99 Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100040120 Prominin-1 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 2
- 230000017274 T cell anergy Effects 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000048776 human CD274 Human genes 0.000 claims description 2
- 102000048362 human PDCD1 Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1500319.7 | 2015-01-09 | ||
| GBGB1500319.7A GB201500319D0 (en) | 2015-01-09 | 2015-01-09 | Anti-PD-L1 antibodies |
| PCT/SG2016/050001 WO2016111645A1 (en) | 2015-01-09 | 2016-01-04 | Anti-pd-l1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508475A JP2018508475A (ja) | 2018-03-29 |
| JP2018508475A5 true JP2018508475A5 (enExample) | 2019-02-14 |
| JP6866294B2 JP6866294B2 (ja) | 2021-04-28 |
Family
ID=52597403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536240A Active JP6866294B2 (ja) | 2015-01-09 | 2016-01-04 | 抗ｐｄ−ｌ１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10517949B2 (enExample) |
| EP (1) | EP3242894B1 (enExample) |
| JP (1) | JP6866294B2 (enExample) |
| KR (1) | KR102713223B1 (enExample) |
| CN (1) | CN107428832B (enExample) |
| AU (1) | AU2016205518B2 (enExample) |
| CA (1) | CA2973332C (enExample) |
| ES (1) | ES2835869T3 (enExample) |
| GB (1) | GB201500319D0 (enExample) |
| SG (1) | SG11201705552QA (enExample) |
| WO (1) | WO2016111645A1 (enExample) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトｃｄ２７に結合する抗体およびその使用 |
| RS57840B1 (sr) | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| CN107686520B (zh) * | 2016-08-04 | 2023-01-03 | 信达生物制药(苏州)有限公司 | 抗pd-l1纳米抗体及其应用 |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| CN107815466B (zh) | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN107773762B (zh) * | 2016-08-31 | 2021-06-15 | 上海干云生物科技有限公司 | 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用 |
| WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
| EP3515951B1 (en) * | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| CA3052084A1 (en) * | 2017-01-09 | 2018-07-12 | Biomunex Pharmaceuticals | A polypeptide linker for preparing multispecific antibodies |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| EP3600357A4 (en) | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| RU2665790C1 (ru) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
| KR20240093758A (ko) | 2017-04-21 | 2024-06-24 | 베이롤 칼리지 오브 메드신 | 종양용해성 바이러스요법 및 면역요법 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| US11421029B2 (en) * | 2017-09-01 | 2022-08-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recombinant bispecific antibodies to PD-L1 and CTLA-4 |
| EP3694545A4 (en) * | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM |
| US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| US11306119B2 (en) | 2017-12-15 | 2022-04-19 | Kyungpook National University Industry-Academic Cooperation Foundation | Peptide bound to PD-L1 and use thereof |
| KR102150419B1 (ko) * | 2017-12-15 | 2020-09-01 | 경북대학교 산학협력단 | Pd-l1에 결합하는 펩타이드 및 이의 용도 |
| CA3086098A1 (en) * | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| KR102311838B1 (ko) * | 2017-12-27 | 2021-10-14 | 주식회사 파멥신 | 항-pd-l1 항체 및 이의 용도 |
| CN109970857B (zh) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| US12174193B2 (en) * | 2018-01-15 | 2024-12-24 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| US11976128B2 (en) | 2018-03-23 | 2024-05-07 | Board Of Regents, The University Of Texas System | Human PD-L2 antibodies and methods of use therefor |
| EP3768723A4 (en) | 2018-03-23 | 2021-12-29 | Board of Regents, The University of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| US12054556B2 (en) | 2018-04-09 | 2024-08-06 | Oricell Therapeutics Co., Ltd. | Anti-PD-L1 antibody and use thereof |
| CA3095498A1 (en) * | 2018-04-09 | 2019-10-17 | Origincell Therapeutics Co., Ltd. | Anti-pd-l1 antibody and use thereof |
| CA3097152A1 (en) * | 2018-04-16 | 2019-10-24 | Memorial Sloan Kettering Cancer Center | T-cell exhaustion, & methods & compositions relating thereto |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| CN112074541A (zh) * | 2018-05-03 | 2020-12-11 | 上海岸迈生物科技有限公司 | Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白 |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| GB201811403D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| AU2019328632A1 (en) | 2018-08-27 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof |
| WO2020081786A1 (en) * | 2018-10-17 | 2020-04-23 | Immunome, Inc. | Exosome-targeting bispecific antibodies |
| EP3870297B1 (en) | 2018-10-25 | 2023-08-30 | Baylor College of Medicine | Oncolytic virotherapy and immunotherapy |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| JP7497351B2 (ja) * | 2018-11-13 | 2024-06-10 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | チェックポイント分子に対する多重特異性結合性構築物およびその使用 |
| KR20210099614A (ko) | 2018-12-04 | 2021-08-12 | 노파르티스 아게 | Cd3에 대한 결합 분자 및 이의 용도 |
| CN113631188A (zh) * | 2018-12-27 | 2021-11-09 | 吉加根公司 | 抗pd-l1结合蛋白及其使用方法 |
| US20220089752A1 (en) * | 2019-01-14 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for modulating cellular internalization |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| JP7302010B2 (ja) * | 2019-04-11 | 2023-07-03 | スクリップス コリア アンチボディ インスティチュート | プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN114341180B (zh) * | 2019-08-23 | 2023-09-22 | 上海药明生物技术有限公司 | 抗pd-l1的人源化抗体 |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| WO2022095970A1 (zh) * | 2020-11-06 | 2022-05-12 | 百奥泰生物制药股份有限公司 | 双特异抗体及其应用 |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN114478789B (zh) * | 2021-12-20 | 2024-06-14 | 安徽安科生物工程（集团）股份有限公司 | 抗pd-l1与ox40双特异性抗体及其用途 |
| CN114470195A (zh) * | 2022-01-19 | 2022-05-13 | 同济大学 | 一种抗真菌制剂、抑制细胞pd-l1表达的抑制剂及应用 |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| WO2023192976A1 (en) | 2022-04-01 | 2023-10-05 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| EP4525991A1 (en) | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
| CN120302979A (zh) | 2022-12-01 | 2025-07-11 | 生物技术公司 | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| CN120981481A (zh) * | 2023-01-10 | 2025-11-18 | 萨那生物技术股份有限公司 | Cd19特异性抗体构建体以及它们的组合物 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| US12649790B2 (en) | 2023-07-03 | 2026-06-09 | Medicovestor, Inc. | Proteins that bind SP17 including fully-human anti-SP17 antibodies |
| US12624097B2 (en) | 2023-07-03 | 2026-05-12 | Medicovestor, Inc. | Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| US12364777B2 (en) | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| US12121587B1 (en) | 2023-12-26 | 2024-10-22 | Medicovestor, Inc. | Dimeric antibodies |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| US12116410B1 (en) | 2023-12-26 | 2024-10-15 | Medicovestor, Inc. | Methods of manufacturing dimeric antibodies |
| US12673991B2 (en) | 2023-12-26 | 2026-07-07 | Medicovestor, Inc. | Methods of crosslinking IgG |
| CN120305419B (zh) * | 2025-06-17 | 2025-11-21 | 中国医学科学院医药生物技术研究所 | 一种pd-l1靶向性仿生外泌体和包含其的药物组合物及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US98415A (en) * | 1869-12-28 | Improved folding chair | ||
| DE60334303D1 (de) * | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| PL1810026T3 (pl) * | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907000T4 (da) | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) * | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP3279215B1 (en) * | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US20140065035A1 (en) * | 2011-04-19 | 2014-03-06 | Bio Focus Co., Ltd. | Method for manufacturing a microvalve device mounted on a lab-on-a-chip, and microvalve device manufactured by same |
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) * | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| HUE054012T2 (hu) | 2014-10-29 | 2021-08-30 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| KR20240093758A (ko) * | 2017-04-21 | 2024-06-24 | 베이롤 칼리지 오브 메드신 | 종양용해성 바이러스요법 및 면역요법 |
| WO2021091560A1 (en) * | 2019-11-07 | 2021-05-14 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN115917316B (zh) * | 2020-06-12 | 2025-10-24 | 新加坡科技研究局 | 嗜中性粒细胞祖细胞及相关方法和用途 |
-
2015
- 2015-01-09 GB GBGB1500319.7A patent/GB201500319D0/en not_active Ceased
-
2016
- 2016-01-04 AU AU2016205518A patent/AU2016205518B2/en active Active
- 2016-01-04 EP EP16735235.0A patent/EP3242894B1/en active Active
- 2016-01-04 ES ES16735235T patent/ES2835869T3/es active Active
- 2016-01-04 SG SG11201705552QA patent/SG11201705552QA/en unknown
- 2016-01-04 JP JP2017536240A patent/JP6866294B2/ja active Active
- 2016-01-04 WO PCT/SG2016/050001 patent/WO2016111645A1/en not_active Ceased
- 2016-01-04 CA CA2973332A patent/CA2973332C/en active Active
- 2016-01-04 CN CN201680014808.2A patent/CN107428832B/zh active Active
- 2016-01-04 US US15/542,023 patent/US10517949B2/en active Active
- 2016-01-04 KR KR1020177021198A patent/KR102713223B1/ko active Active
-
2017
- 2017-06-15 US US15/623,679 patent/US9789183B1/en active Active
-
2019
- 2019-10-09 US US16/597,586 patent/US11534489B2/en active Active
-
2022
- 2022-11-23 US US18/058,699 patent/US12472252B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519208A5 (enExample) | ||
| JP2018500924A5 (enExample) | ||
| AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
| JP2018527912A5 (enExample) | ||
| US11690908B2 (en) | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy | |
| JP2017536111A5 (enExample) | ||
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP6866294B2 (ja) | 抗ｐｄ−ｌ１抗体 | |
| JP7038353B2 (ja) | エクスビボのｂｉｔｅ活性化ｔ細胞 | |
| JP2017538441A5 (enExample) | ||
| US20230227553A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| JP2020522489A5 (enExample) | ||
| JP2022514262A (ja) | 双子型免疫細胞エンゲージャー | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| JP2020530989A5 (enExample) | ||
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| JP2019519208A (ja) | 抗ｃｔｌａ−４抗体 | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP2017510251A (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP2018508215A5 (enExample) | ||
| JP2017532005A5 (enExample) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP6933724B2 (ja) | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 |